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Abstract
Triptolide (TPL), a key biologically active component of the Chinese medicinal herb Tripterygium wilfordii Hook. f., has potent
anti-inflammation and anti-cancer activities. Its anti-proliferative and pro-apoptotic effects have been reported to be related
to the inhibition of Nuclear Factor kB (NF-kB) and Nuclear Factor of Activated T-cells (NFAT) mediated transcription and
suppression of HSP70 expression. The direct targets and precise mechanisms that are responsible for the gene expression
inhibition, however, remain unknown. Here, we report that TPL inhibits global gene transcription by inducing proteasome-
dependent degradation of the largest subunit of RNA polymerase II (Rpb1) in cancer cells. In the presence of proteosome
inhibitor MG132, TPL treatment causes hyperphosphorylation of Rpb1 by activation of upstream protein kinases such as
Positive Transcription Elongation Factor b (P-TEFb) in a time and dose dependent manner. Also, we observe that short time
incubation of TPL with cancer cells induces DNA damage. In conclusion, we propose a new mechanism of how TPL works in
killing cancer. TPL inhibits global transcription in cancer cells by induction of phosphorylation and subsequent proteasome-
dependent degradation of Rpb1 resulting in global gene transcription, which may explain the high potency of TPL in killing
cancer.
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Introduction
The Chinese medicinal herb Tripterygium wilfordii Hook. f. has been
used for centuries to treat inflammation, autoimmune diseases, and
cancers [1,2]. Triptolide (TPL), a diterpenoid triepoxide, is one of the
major biologically active components of the herb. Many studies have
revealed that TPL has a myriad of biological functions, including
immunosuppression, anti-inflammation, and anti-cancer, since its
first isolation in 1972 [1,3,4,5]. Although the activity of TPL in
inducing tumor cell death has been well documented, its modes of
action have not been thoroughly elucidated. TPL has been mostly
reported to reduce mRNA levels of many genes. It has been reported
to strongly inhibit transcription of numerous pro-inflammatory
mediators [6]. It is a potent inhibitor of NF-kB and NFAT-mediated
transcription [7]. It is also an inhibitor of the transcription of HSP 70
[8]. Recently, there have been reports demonstrating that TPL has
global transcriptional inhibitory activities [9,10,11]. The precise
mechanism of TPL, however, is not well characterized. Based on
these observations, it is reasonable to speculate that a global
transcriptional inhibition may be the key for TPL to exert its potent
antitumor activities against a broad range of human cancers.
RNA polymerase II (Pol II) is a large protein complex of 12
subunits. It is involved not only in transcription but also in other
biological processes in the nucleus, including mRNA processing
and transcription-coupled repair (TCR) [12,13,14]. The largest
subunit, Rpb1, contains a unique C-terminal domain (CTD) that
consists of the heptapeptide Tyr-Ser-Pro-Thr-Ser-Pro-Ser repeat-
ed 52 times in mammalian cells [12,14,15]. Pol II undergoes post-
translational modifications, such as phosphorylation and ubiqui-
tination [16,17]. Phosphorylation of the CTD of Rpb1 has
specialized roles. First, CTD undergoes a cycle of phosphoryla-
tion/dephosphorylation during the transcription cycle [18,19]. At
the beginning of transcription, a hypophosphorylated form of Pol
II (IIA) preferentially binds to promoters. Later on, promoter
clearance and transcript elongation are associated with phosphor-
ylation of the CTD to yield a hyperphosphorylated form (IIO).
Second, the phosphorylated CTD plays an important role in
mRNA processing because many proteins involved in pre-mRNA
processing bind to the phosphorylated CTD [14,20]. Third, many
studies reveal that DNA damage by UV or hydrogen peroxide
(H2O2) induces phosphorylation of CTD of Rpb1 accompanied
with ubiquitination and subsequent proteasome degradation.
When the DNA lesions are located on the transcribed strand of
a gene, cells trigger TCR to remove the lesion. In TCR, the
progression of Pol II is blocked at the DNA lesions within the
coding region. Stalled Pol II needs to be removed from the site of
damage in order for the repair machinery to assemble, possibly by
phosphorylation-mediated proteolysis [12,17,21]. Several kinases
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and JNK have been shown to be responsible for the phosphor-
ylation of CTD under different conditions [12,14,22,23,24].
In our study, it was found that TPL inhibited global gene
transcription, which was consistent with a recent discovery [9,11].
Detailed studies revealed that TPL induced phosphorylation and
subsequent proteasome degradation of Rpb1 in a dose and time-
dependent manner in cancer cell lines. The protein kinase P-TEFb
is required for the TPL-induced phosphorylation of Rpb1. We also
observed DNA damage induced by TPL using comet assay. We
propose that DNA damage-trigged phosphorylation and degrada-
tion of Rpb1 may be the key for a global transcriptional inhibition
by TPL. Our study uncovered a new mechanism of TPL in
inducing cancer cell death.
Results
TPL inhibited global transcription in cancer cells
In an attempt to understand the molecular mechanisms of TPL
in inducing cancer cell death, we used Real-time PCR to examine
the effects of TPL on the transcription of several inducible and
housekeeping genes. The results showed that short-time treatment
of TPL in Hela cells strongly suppressed Wnt, TNF-a or IFN-b
induced target genes transcription (Fig. 1A). Similar inhibitory
effects were observed on housekeeping gene b-Actin and GAPDH
when Hela cells were treated with TPL for 12 h (Fig. 1B). We also
examined the effect of TPL on transcription of a transiently
transfected gene pEGFP-N1 in Hela cells. 6 h after transfection,
the Hela cells were treated with TPL for another 15h. We found
that GFP expression was dramatically inhibited by TPL (Fig. 1C).
Taken together, these data strongly suggested that TPL inhibited
global transcription.
TPL reduced Rpb1 protein level in cancer cell lines
To understand how TPL may affect global transcription, we
analyzed the effects of TPL on the components of RNA
polymerase II, because Pol II plays a crucial role in transcription.
We first investigated the effects of TPL on the largest subunit of
Pol II, Rpb1, by immunoblotting. We found that TPL reduced the
protein level of Rpb1 in a dose-dependent manner in Hela cells
(Fig. 2A). The decrease of Rpb1 protein level was evident at 1 h
incubation with 125 nM of TPL, and reached maximum at 2 h
(Fig. 2B). We also examined the effect of TPL on Rpb1 in other
cancer cell lines, MDA-MB-453, MDA-MB-231 and MDA-MB-
468 (Fig. 2C). Similar effects were observed when these cells were
incubated with TPL for 3 h. All these results demonstrated that
TPL reduced the protein level of Rpb1 in cancer cells.
TPL induced phosphorylation and subsequent
proteasome-dependent degradation of Rpb1
To address whether the reduction of Rpb1 protein level by
TPL is due to inhibition of protein synthesis or induction of
protein degradation, we examined the effects of TPL on Rpb1
protein level in the presence of protein synthesis inhibitor
cycloheximide (CHX) or proteasome inhibitor MG132. The
results showed that TPL still reduced Rpb1 protein levels in the
presence of CHX (Fig. 3A). On the contrary, the decrease of
Rpb1 protein level by TPL was inhibited by the MG132
treatment (Fig. 3B), suggesting that TPL reduced Rpb1 protein
levels through a proteasome-dependent protein degradation
mechanism. Furthermore, we found that the recovered Rpb1
was mostly in the phosphorylated form (Pol IIO) when the TPL-
induced proteasomal degradation of Rpb1 was inhibited by
MG132, and the phosphorylation of Rpb1 induced by TPL was
also in a dose and time dependent manner (Fig. 3B and 3C).
These results indicated that TPL induced phosphorylation of
Rpb1 and the phosphorylated Rpb1 subsequently underwent
proteasome-dependent degradation.
TPL increased phosphorylation of Rpb1 by activating
protein kinases
We further investigated whether the increased phosphorylation
of Rpb1 induced by TPL is caused by kinase activation or
phosphatase inactivation. We first compared the effect of TPL
with that of the general serine/theronine phosphatase inhibitor,
NaF, on Rpb1.We found that different from the effect of TPL,
inhibition of phosphatase by NaF treatment did not increase the
phosphorylation level of Rpb1 in the presence of MG132
(Fig. 4A), suggesting that the increased phosphorylation of
Rpb1 induced by TPL was not due to phosphatase inactivation.
In addition, we examined the phosphorylation of IKK a/b as a
positive control of phosphatase inhibition by NaF. We found that
TPL did not increase the phosphorylation of IKK a/b,
suggesting that the phosphorylation of Rpb1 by TPL was specific
(Fig. 4A).
Next, we determined if the TPL-induced phosphorylation of
Rpb1 was due to kinase activation by using a general protein
kinase inhibitor H7. It was found that the phosphorylation of
Rpb1 induced by TPL was inhibited by H7 when the proteasomal
degradation of Rpb1 was blocked by MG132 (Fig. 4B), suggesting
that TPL induced phosphorylation of Rpb1 by activating kinases.
To identify the exact kinase responsible for the TPL-induced
phosphorylation, we used several specific kinase inhibitors
targeting ERK, JNK or P-TEFb which are reported to
phosphorylate Rpb1 [12,25]. Only the P-TEFb inhibitor DRB
partially inhibited the phosphorylation of Rpb1 (Fig. 4C) while the
other two inhibitors had no effects on phosphorylation of Rpb1
(data not shown). P-TEFb is a complex of CDK9 and Cyclin T1.
We further investigated the role of P-TEFb in TPL-induced Rpb1
phosphorylation by transfection of siRNAs of CDK9 and Cyclin
T1 into Hela cells. The data demonstrated that the TPL-induced
phosphorylation of Rpb1 was decreased when the protein levels of
CDK9 and Cyclin T1 were reduced (Fig. 4D), which is consistent
with result of the pharmacological inhibition of P-TEFb. These
data strongly suggested that TPL-induced Rpb1 phosphorylation
was regulated by P-TEFb.
TPL induced DNA damage
It is reported that UV or H2O2-induced DNA damage leads to
phosphorylation and subsequent proteasomal degradation of
Rpb1 to allow TCR to repair the DNA lesion [12,14]. We
therefore investigated whether the TPL-induced phosphorylation
and degradation of Rpb1 was due to DNA damage. We
examined the effect of TPL on DNA damage by comet assay,
which is also known as single cell gel electrophoresis assay to
detect DNA damage in a single cell. The overall structure of
genome DNA resembles a comet with a circular head
corresponding to the undamaged DNA and a tail of damaged
DNA. The brighter and longer the tail is, the higher the level of
the damage is [26]. As shown in Fig. 5A, 3 h-treatment of TPL in
Hela cells induced DNA damage at 125 nM while more comet
tails appeared at 500 nM (Fig. 5A), suggesting that TPL induced
DNA damage. At this time point, TPL had no obvious effects on
the morphology as well as apoptosis of Hela cells (Fig. 5B–5D),
ruling out the possibility that comet tails caused by TPL were the
result of apoptosis.
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e23993Figure 1. TPL inhibited global transcription. (A) Effects of TPL on the transcription of inducible genes. Hela cells were pretreated with TPL at
indicated concentrations for 2 h before stimulation by LiCl (20 mM), TNF-a (100ng/ml) or IFN-b (100ng/ml) for another 3 h. The mRNA expression of
the indicated genes was analyzed by Real-time PCR. All values were normalized to the mRNA level of b-Actin because the mRNA level of b-Actin was
not affected at this time point. (B) Effects of TPL on the transcription of housekeeping genes. Hela cells were treated with TPL for 12 h. The mRNA
expression of the indicated genes was analyzed by Real-time PCR. Equal amounts of RNA were used to normalize the loadings. (C) Effects of TPL on
expression of transiently transfected genes. Hela cells were transiently transfected with a pEGFP-N1 plasmid. 6 h after transfection, the medium was
replaced with the fresh medium containing TPL at indicated concentrations and the Hela cells were incubated for another 15h. GFP expression was
visualized by fluorescent microscopy. The picture is a representative of four visual fields. Original magnification: 6200.
doi:10.1371/journal.pone.0023993.g001
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Tripterygium wilfordii Hook. f. has long been used as a folk
medicine to treat cancer in China. TPL is one of the major active
components of the plant, which possesses strong anti-cancer
activity against leukemias, lymphomas, as well as solid tumors
[27]. The mode of action of its anti-neoplastic effect is complex
and not well-characterized. Thus, elucidating the molecular
mechanism of TPL in killing cancer cells will help us to understand
and to better use this traditional Chinese medicine in cancer
therapy.
Many studies have been carried to elucidate the mode of action
of TPL in inducing cancer cell death. The conclusions are
however diverse. It has been reported that its pro-apoptotic
activity is due to modulation of apoptosis-activating proteins
[28,29] and is partially dependent on calcium [30]. It was found
that cancer cell-specific enhancement of cisplatin-induced cyto-
toxicity with TPL was through an interaction of inactivated
glycogen synthase kinase-3 with p53 [31]. It was also reported that
TPL suppressed NF-kB, AP-1, NFAT, and HSF1 transactivation,
and the inhibition of NF-kB and HSF1 was at a step following
their DNA binding [7,32,33]. In contrast to above studies, which
all point to certain specificities of TPL, TPL has also been reported
to suppress general transcription by altering nuclear substructure
[9]. It appeared from these studies that TPL influences many
Figure 2. Effects of TPL on Rpb1 protein levels. (A) Hela cells were treated with TPL at indicated concentrations for 3 h. Whole cell lysates were
processed for SDS-PAGE and Western blot analysis using antibodies as indicated. (B) Hela cells were treated with 125 nM TPL for various lengths of
time (0–180 min) as indicated. Whole cell lysates were subjected to SDS-PAGE and Western blot analysis. (C) MDA-MB-453, MDA-MB-231 or MDA-MB-
468 cells were treated with 125 nM TPL for 3 h. Whole cell lysates were subjected to SDS-PAGE and Western blot analysis. b-Actin served as a loading
control.
doi:10.1371/journal.pone.0023993.g002
Figure 3. TPL induced phosphorylation and proteasome-dependent degradation of Rpb1. (A) Hela cells were pretreated with CHX
(10 mM) for 0.5 h before addition of TPL (125 nM) and treated for another 3 h. Whole cell lysates were processed for Western blot analysis using
antibodies as indicated. (B) Hela cells were pretreated with MG132 (20 mM) for 1 h and then treated with TPL at indicated concentrations for another
3 h. Whole cell lysates were subjected to SDS-PAGE and Western blot analysis. (C) Hela cells were treated with 125 nM TPL for various lengths of time
(0–180 min) in the presence of MG132 (20 mM). Whole cell lysates were subjected to SDS-PAGE and Western blot analysis. b-Actin served as a loading
control.
doi:10.1371/journal.pone.0023993.g003
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survival. The direct targets of TPL, however, remain unidentified.
We observed several effects of TPL on cancer cells in our study.
First, TPL inhibited global transcription in cancer cells. Second,
short-time treatment of TPL induced a proteasome-dependent
degradation of Rpb1, the largest subunit of RNA polymerase II.
Third, TPL increased phosphoryalation of Rpb1 by activating
protein kinases such as P-TEFb. Fourth, short-time treatment of
TPL induced DNA damage in cancer cells.
It is not clear how the TPL-induced DNA damage may activate
P-TEFb. However, it is known that P-TEFb is a major kinase of
Rpb1, and cells trigger TCR to activate kinases to specifically
repair DNA lesions located in the transcribed strand of DNA in
the UV or H2O2-induced DNA damage [12,14]. During TCR,
Rpb1 undergoes phosphorylation which signals for proteasome-
dependent degradation. The effects of TPL on Rpb1 seem similar
to those of UV which caused P-TEFb activation as well as
subsequent phosphorylation and degradation of Rpb1. It is logic to
hypothesize that DNA is the primary target of TPL. TPL causes
DNA damage, which in turn triggers TCR, then activates certain
protein kinases, such as P-TEFb, to phosphorylate Rpb1. The
phosphorylated Rpb1 is subsequently targeted to proteosome to be
degraded. The transcription of the targeted cells is therefore
inhibited, which ultimately causes cancer cells to die. The dose of
TPL to cause DNA damage is higher than that to induce
phosphorylation of Rpb1 because of the sensitivity of the comet
assay. It requires a large amount of DNA damage, therefore a high
dose of TPL, to give rise to a visible effect. The Rpb1
phosphorylation assay however is far more sensitive than the
comet assay, which is the reason why the doses of TPL were
different in the two assays.
We do not think the DNA damage we observed is the result of
cell apoptosis because we did not observe apoptosis when we
observed the DNA damage. Our experiments also exclude the
possibility that TPL may induce ROS to cause the degradation of
Rpb1 (data not shown). It has been reported that compounds
posses epoxy groups are reported to alkylate DNA and the epoxy
groups are responsible for this reactivity [34]. There are three
epoxy groups in TPL which may alkylate DNA and result in DNA
damage, although we have not obtained direct evidences to
support our hypothesis.
In summary, our study discovered a new mode of action of TPL in
anti-cancer therapy. TPL inhibited global transcription by inducing
DNA damage and Rpb1 degradation in cancer cells. Global
transcriptional inhibition induces apoptosis in cancer cells [35,36,37].
Our discovery may explain the high efficacy of TPL against a wide
range of cancers. As the mode of action of TPL continues to unfold, we
will eventually understand the multiple regulatory actions of TPL on
cancer cells as well as its therapeutic potentials.
Materials and Methods
Cell Lines and Culture
All the cancer cell lines used, cervix cancer cell line Hela and
breast cancer cell lines MDA-MB-231, MDA-MB-453 and MDA-
MB-468, were obtained from the American Type Culture
Collection (ATCC) and were cultured in DMEM containing
10% calf serum and 1% penicillin-streptomycin.
Reagents
Triptolide, proteasome inhibitor MG132, and protein synthesis
inhibitor cycloheximide (CHX) were purchased from Calbiochem.
Figure 4. TPL induced phosphorylation of Rpb1 by activation of protein kinases. (A) Comparison of the effect of TPL with NaF on Rpb1.
Hela cells were treated with TPL or NaF for 3 h in the presence/absence of MG132. Whole cell lysates were processed for SDS-PAGE and Western blot
analysis using antibodies as indicated. (B) Hela cells were pretreated with MG132 for 1 h, and then treated with TPL in the presence/absence of 50 mM
H7 for 3 h. Whole cell lysates were subjected to SDS-PAGE and Western blot analysis. (C) Hela cells were pretreated with MG132 for 1 h, and then
treated with TPL in the presence/absence of 50 mM DRB for 3 h. Whole cell lysates were subjected to SDS-PAGE and Western blot analysis. (D)
Analysis of effect of CDK9 and Cyclin T1 siRNA on TPL-induced Rpb1 phosphorylation. Hela cells were transfected with NC (negative control) or CDK9
and Cyclin T1 siRNA. 48 h after transfection, the Hela cells were pretreated with 20 mM MG132 for 1 h. Then the cells were treated with DMSO or 125
nM TPL for another 3 h before collected to SDS-PAGE and Western blot analysis. b-Actin served as a loading control.
doi:10.1371/journal.pone.0023993.g004
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theronine phosphatase inhibitor NaF were purchased from Sigma.
Plasmids and Transfection
pEGFP-N1 was obtained from Clonetech and transient
transfection of Hela cells with pEGFP-N1 was performed using
Lipofectamine 2000 (Invitrogen).
Western Blot Analysis
Whole cell lysates were prepared in 16Laemmli sample buffer
(Sigma) to extract total proteins. Equivalent amounts of total
cellular protein were resolved by a 7.5% SDS- PAGE and
transferred onto nitrocellulose membranes (Millipore). The
membranes were blocked in 5% nonfat milk in TBS containing
0.1% Tween 20 (TBST) for 1 h at room temperature, and then
incubated with primary antibodies in 5% bovine serum albumin
(BSA) in TBST at 4uC overnight. The membranes were then
washed with TBST and incubated with horseradish peroxidase-
conjugated secondary antibody in 5% BSA in TBST for 1 h at
room temperature. Immune complexes were detected by en-
hanced chemiluminescence (Pierce).
Antibodies used in Western blotting were rabbit anti-Rpb1,
rabbit anti-Cyclin T1and rabbit anti-CDK9 (Santa Cruz Biotech-
nology); rabbit anti-phospho-IKK a/b and rabbit anti-PARP (Cell
Signaling Technology); mouse anti-b-Actin (Sigma).
Real-time PCR
Total cellular RNA was isolated with TRIzol (Invitrogen)
according to the manufacturer’s instructions. Reverse transcrip-
tion of purified RNA was performed using oligo(dT) primer. The
quantification of gene transcripts performed by real-time PCR
using SYBR Green I dye (Invitrogen). All values of inducible
genes were normalized to the level of b-Actin mRNA. For
accessing the mRNA levels of the housekeeping genes b-Actin
and GAPDH, equal amounts of RNA were used for their
normalization.
siRNA knockdown
Small interfering RNAs (siRNAs) for the negative control (NC),
CDK9 and Cyclin T1 were purchased from GenePharma and
transfected using lipofetamine 2000 (Invitrogen). The sequences of the
siRNA oligonucleotides used in this study were as follows: NC siRNA,
5-UUCUCCGAACGUGUCACGUTT- 3 ;C D K 9s i R N A ,5 - U -
AGGGACAUGAAGGCUGCUAA-3; Cyclin T1 siRNA, 5-UCC-
CUUCCUGAUACUAGA A-3. Hela cells were plated in 6-well
plates. At 40% confluence, 150 pmol of NC siRNA or 75 pmol CDK9
and 75 pmol Cyclin T1 siRNA were transfected into cells. 48 h
posttransfection, the Hela cells were pretreated with 20 mM MG132
for 1 h. Then the cells were treated with DMSO or 125 nM TPL for
another 3 h before collected to Western blot analysis. Efficiency of
protein knock down was determined at this time point.
Alkaline single-cell gel electrophoresis assay (comet
assay)
The alkaline single-cell gel electrophoresis assay was performed
as previously described [38,39]. Briefly, HeLa cells were treated
with TPL for 3 h before being pelleted and resuspended in ice-
cold PBS. Resuspended cells were then mixed with prewarmed
1% low–melting point agarose. The agarose-cell mixture was
placed on a slide pre-coated with 0.5% agarose and spread gently
with a cover slip. After 15 min at 4
oC, the slides were immersed in
precooled lysis solution (2.5 M NaCl, 100 mM Na2EDTA,
10 mM Tris-HCl (pH 10), 10% DMSO, 1% Triton X-100, and
1% laurosylsarcosinate) for 90 min in a dark chamber. After
soaking with electrophoresis buffer (0.3 M NaOH and 1 mM
EDTA) for 20 min, the slides were subjected to electrophoresis for
20 min. Finally, the cells were stained with DAPI. Cells were
viewed using an Olympus BX51 fluorescence microscope and
quantitation was achieved by analyzing at least 50 randomly
selected comets per slide with the Komet 5.5 software (Kinetic
Imaging Ltd., Nottingham, UK) using the parameter olive tail
moments (arbitrary units, defined as the product of the percentage
of DNA in the tail multiplied by the tail length).
Determination of cell viability
Hela cells were treated with TPL for 3 h and then cell viability
was determined by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenylte-
trazolium Bromide (MTT) Assay as described [40].
Figure 5. TPL induced DNA damage. (A) Comet assay. Hela cells
were treated with TPL at indicated concentrations for 3 h, and then
subjected to comet assay. Quantification analysis of the results was
presented below the graph. The pictures are representatives of four
fields. Original magnification: 6200. (B) Morphology of Hela cells
treated with TPL at indicated concentrations for 3 h. The pictures are
representatives of four fields. Original magnification: 6200. (C) Viability
of Hela cells treated with TPL at indicated concentrations for 3 h. (D)
Apoptosis analysis of Hela cells treated with TPL at indicated
concentrations for 3 h. Whole cell lysates were processed for Western
blot analysis using anti-PARP antibody. b-Actin served as a loading
control.
doi:10.1371/journal.pone.0023993.g005
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